NEW YORK Sept. 29, 2021 / PRNewswire / – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotechnology company developing therapies, is pleased to announce the addition of Bryan L. Roth MD, PhD to its Scientific Advisory Board.
[19459013MindwsMedicinelogoMindwsMedicine(194590014002] [19459013MindwsMedicinelogo/
Inc. (Mindmed))
Dr. Roth has spent more than 30 years studying molecular neuropharmacology. He is Michael Hooker Distinguished Professor in the Department of Pharmacology, University of North Carolina School of Medicine ( UNC ). He is also the director of the Psychoactive Drug Detection Program of the National Institute of Mental Health.
Dr. Roth's research focuses on eliminating the hallucinogenic effects of psychedelic drugs; eliminate the hours-long hallucinatory trips that can steer some patients away from psychedelic-assisted treatments. He was one of the first to publish in the scientific journal Cell, the structure of how LSD binds to serotonin receptors within the brain. This structure is crucial in helping scientists understand why psychedelics can have hallucinogenic and therapeutic effects.
Dr. Roth's search for drugs that bind to serotonin receptors and activate them without causing a psychedelic experience won a grant $ 27 million from the Defense Advanced Research Projects Agency, a defense agency. research and development of the US Department of Defense technologies. The grant helped fund Ultra Large-Scale-Docking, a computer program that can generate 1 billion theoretical psychedelic compounds that score differently in the way they activate the serotonin 5-HT-2A receptor. Dr. Roth's team is studying the compounds identified by Ultra Large-Scale-Docking that are most likely to activate the serotonin receptor without triggering hallucinations.
MindMed CEO Robert Barrow said, "We are delighted to welcome Dr. Roth to our Scientific Advisory Board. As we seek to reinvent mental health and addiction care, we want to make sure that the treatments we are studying are effective and accessible to as many patients as possible. Dr. Roth's extensive experience in psychiatry and pharmacology will be invaluable in advancing all of our research and development efforts. "
Dr. Roth noted: "Psychedelic compounds like psilocybin have some of the strongest antidepressant effects I've seen in phase II studies. But not all patients feel comfortable with their treatment program requiring hallucinatory trips My research and perspective excite me to incorporate into drug development programs at MindMed, focuses on how we can make drugs that are most useful to patients while minimizing discomfort in the treatment process. "
MindMed's Scientific Advisory Council is comprised of a diverse group of members with backgrounds in psychiatry, neuroscience, and clinical development. The Scientific Advisory Board draws on decades of experience in biotechnology and psychiatry to guide MindMed's development programs. Members represent institutions such as Johns Hopkins University New York University Langone Health, Duke University National Institutes of Health, Stanford University and Massachusetts General Hospital.
About MindMed
MindMed is a clinical-stage psychedelic medicine biotechnology company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. MindMed is assembling a compelling drug development line of innovative psychedelic-based treatments including psilocybin, LSD, MDMA, DMT, and an ibogaine derivative, 18-MC. MindMed's executive team brings extensive biopharmaceutical expertise to MindMed's approach to developing the next generation of psychedelic-inspired drugs and therapies.
MindMed is listed on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also marketed in Germany under the symbol MMQ.
Forward-Looking Statements
Certain Statements in this Notice Company-related communications constitute "forward-looking information" within the meaning of applicable securities laws and are forward-looking in nature. . Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and, therefore, is subject to risks and uncertainties that could cause actual results to differ materially from future results expressed or Implicit in the Forward-Looking Statements. . These statements can generally be identified by using forward-looking words such as "will", "could", "should", "could", "intend", "estimate", "plan", "anticipate", "expect ". "," believe "," potential "or" continue ", or the negative thereof or similar variations. Forward-looking information in this press release includes, but is not limited to, statements regarding MindMed's Scientific Advisory Committee, research by Dr. . Roth on psychedelic drugs and their potential discoveries and MindMed's ability to harness the knowledge and experience of its Scientific Committee members. Advisory Board. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information implies risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on the Company's future results, performance, or achievements. There are numerous risks and uncertainties that could cause the actual results and the plans and objectives of the Company differ materially from those expressed in the to forward-looking information, including negative cash flow history; limited operating history; incur future losses; availability of additional capital; lack of income from products; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; increased regulatory scrutiny; early stage product development; risks of clinical trials; regulatory approval processes; new from the psychedelic-inspired drug industry; as well as the risk factors discussed or mentioned in this document and the risks described under the headings "Risk Factors" in the Company's records with the securities regulatory authorities in all provinces and territories of Canada which are available under the profiles on SEDAR at www.sedar.com and with the US Securities and Exchange Commission on EDGAR at www.sec.gov. If one or more of these risks or uncertainties materialize, or if the assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify significant risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results to be different from those anticipated, estimated or anticipated. This and all subsequent written and oral forward-looking information are based on management's estimates and opinions as of the dates made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not undertake any obligation to update this forward-looking information.
Media contact: mindmed@150bond.com
V See original content to download multimedia: https: //www.prnewswire.com/news-releases/mindmed-appoints-university-of-north-carolina-psychiatrist-and-pharmacologist-dr-bryan- roth-to-scientific-advisory-board-301387396.html
SOURCE Mind Medicine (MindMed) Inc.
See original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2021 /29/c8472.html[19459007
Be First to Comment